LIMK1 and open-angle glaucoma: The pyrrolopyrimidines LX7101 (3), developedby Lexicon Pharmaceuticals, and SR7826 (4, Figure ) have also been disclosedas potent type I LIMK inhibitors.−, 3is a dualLIMK/ROCK inhibitor that advanced to phase 1/2a clinical trials forprimary open-angle glaucoma or ocular hypertension.4, an analogue devoid of ROCK inhibition,protects against Aβ-induced hippocampal thin spine loss, dendriticspine degeneration and rescues impairedhippocampal long-term potentiation in neonatal Fmr1 KO mice. However, both 3 and 4 remain as unselective, type I LIMK1/2 inhibitors.,